Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2018-2024

  Ragaz, Joseph ^a   Coldman, Andrew ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; ENDOMETRIUM CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECOND CANCER; THROMBOEMBOLISM;

EID: 0031778632     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2018     Document Type: Article

References (79)

1. Harper MJ, Walpole AL: A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fertil 13:101-119, 1967
2. Cole MP, Jones CT, Todd ID: A new anti-oedrogenic agent in late breast cancer. An early clinical appraisal of ICI 46, 474. Br J Cancer 25:270-275, 1971
3. Sherman BM, Chapler FK, Crickard K, et al: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64:398-404, 1979
4. Manni A, Trujillo JE, Marshall JS, et al: Antihormone treatment of stage IV breast cancer. Cancer 43:444-450, 1979
5. Rose C, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res 91:230-242, 1984
6. Stewart HJ, Forrest AP, Gunn JM, et al. The tamoxifen trial - A double blind comparison with stilboestrol in post-menopausal women with advanced breast cancer; in Mouridsen HT, Palshof T (eds): Breast Cancer: Experimental and Clinical Aspects. Proceeding of the Second EORTC Breast Cancer Working Conference, Copenhagen, 1979. New York, NY, Pergamon, 1980; pp 83-88
7. Riberio GG: A clinical trial to compare the use of tamoxifen versus stilboestrol. Rev Endocr Relat Cancer 9:409-414, 1980
8. Pritchard KI, Thompson DB, Meyers RE, et al: Tamoxifen therapy in pre-menopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787-796, 1980
9. Henderson IC: Endocrine therapy of metastatic breast cancer, in Harris JR, Hellman S. Henderson IC, et al (eds): Breast Diseases (ed 2). Philadelphia, PA, Lippincott, 1991, pp 559-603
10. Rose C, Thorpe SM, Andersen KW, et al: Beneficial effect of adjuvant tamoxifen in primary breast cancer patients with high oestrogen receptor values. Lancet 1:16-19, 1985
11. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
12. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171-175, 1987
13. Ribeiro G, Swindell R: The Christie Hospital adjuvant tamoxifen trial status at 10 years. Br J Cancer 57:601-603, 1988
14. Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983
15. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294, 1991
16. Wallgren A, Glas U, Gustafsson S, et al: Effects of adjuvant therapy in primary breast cancer in relation to the estrogen receptor level. Recent Results Cancer Res 91:214-219, 1984
17. Carbone PP, Gray R, Tormey DC: Adjuvant treatment with tamoxifen: The Eastern Cooperative Group (ECOG) experience. Rev Endocr Relat Cancer 17:65-70, 1985 (suppl)
18. Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet 1:836-840, 1985
19. Rutqvist LE, Cedermark B, Glas U, et al: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10:255-266, 1987
20. Pritchard KI, Meakin JW, Boyd NF, et al: Adjuvant tamoxifen in post-menopausal women with axillary node-positive breast cancer: An update, in Salmon SE (ed): Adjuvant Therapy of Cancer V. Orlando, FL, Grune & Stratton, 1987, pp 391-400
21. Swedish Breast Cancer Cooperative Group: Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal early-stage breast cancer. Proc Amer Soc Clin Oncol 15:126, 1996 (abstr)
22. Fisher B, Brown A, Wolmark N, et al: Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106:649-654, 1987
23. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 11:117-120, 1992
24. Cummings FJ, Gray R, Tormey DC, et al: Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death. J Clin Oncol 11:29-35, 1993
25. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320:479-484, 1989
26. CRC Adjuvant Breast Trial Working Party: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604-607, 1988
27. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989
28. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995
29. Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339-346, 1984
30. Bruning PF, Bonfrer JM, Hart AA, et al: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497-499, 1988
31. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327-1332, 1990
32. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. The Scottish Breast Cancer Committee. BMJ 303:435-437, 1991
33. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993
34. Costantino JP, Kuller LH, Ives DG, et al: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89: 776-782, 1997
35. Schapira DV, Kumar NB, Lyman GH: Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat 17:3-7, 1990
36. Anker G, Lonning PE, Ueland PM, et al: Plasma levels of the atherogenio amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 60:365-368, 1995
37. Brunning PF, Bonfrer JM, Hart AA, et al: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497-499, 1988
38. Turken S, Siris E, Seldin D, et al: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989
39. Gotfredsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53:853-857, 1984
40. Love RR, Mazess RB, Tormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297-302, 1988
41. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
42. Jordan VC, Naylor KE, Dix CJ, et al: Anti-oestrogen action in experimental breast cancer. Recent Results Cancer Res 71:30-44, 1980
43. Cuzick J, Wang DY, Bulbrook RD: The prevention of breast cancer. Lancet 1:83-86, 1986
44. Powles TJ, Davey J, Mckinna A: Chemoprevention of breast cancer. Acta Oncol 28:865-867, 1989
45. Powles TJ, Hardy JR, Ashley SE, et al: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126-131, 1989
46. Jordan VC: Long-term adjuvant tamoxifen therapy for breast cancer: The prelude to prevention. Cancer Treat Rev 17:15-36, 1990
47. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82:18-21, 1990
48. Powles TJ, Tillyer CR, Jones AL, et al: Prevention of breast cancer with tamoxifen: An update on the Royal Marsden Hospital Pilot Programme. Eur J Cancer 26:680-684, 1990
49. Fisher B, Redmond CK, for the NSABP Trials Committee: A clinical trial to determine the worth of tamoxifen for preventing breast cancer. The NSABP Protocol P-1, 1991
50. Love RR: Antiestrogen cancer chemoprevention of breast cancer: Critical issues in research. Prev Med 20:64-78, 1991
51. Nayfield SG, Karp JE, Ford LG, et al: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991
52. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237-238, 1985
53. Hardell L: Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 2:1432, 1988 (letter)
54. Mathew A, Chabon AB, Kabakow B, et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. New York State J Med 90:207-208, 1990
55. Jordan VC, Gottardis MM, Satyaswarooop PG: Tamoxifen-stimulated growth of human endometrial carcinoma. Ann NY Acad Sci 622:439-446, 1991
56. Andersson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31:259-263, 1992
57. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
58. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
59. Lutz JM, Chouillet AM, Coleman MP: Endometrium cancer after tamoxifen treatment for breast cancer: A population-based case-control study (abstract c23), in XIXeme Reunion du Groupe Pour l'Epidemiologie et l'Enregistrement du Cancer Dans les Pays de Langue Latin. Granada, 1994, p 24
60. Sasco AJ, Chaplain G, Amoros E, et al: Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radio-therapy. Epidemiology 7:9-13, 1996
61. NSABP Prevention Trial Protocol NSABP-P1, Update, 1994. National Surgical Adjuvant Breast and Bowel Project
62. Hendrick A, Subramanian VP: Tamoxifen and thromboembolism. JAMA 243:514-515, 1980
63. Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517-4519, 1987
64. Cummings FJ, Gray R, Davis TE, et al: Adjuvant tamoxifen treatment of elderly women with stage II breast cancer: A double-blind comparison with placebo. Ann Int Med 103:324-329, 1985
65. Adami HO, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer: Cumulative and relative risks in a population-based case-control study. Cancer 55:643-647, 1985
66. Hislop TG, Elwood JM, Coldman AJ, et al: Second primary cancers of the breast: Incidence and risk factors. Br J Cancer 49:79-85, 1984
67. International Classification of Diseases (ed 9), Clinical Modification: ICD-9-CM. Ann Arbor, MI, Commission on Professional and Hospital Activities, 1978
68. Magriples U, Naftolin F, Schwartz PE, et al: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485-490, 1993
69. Barakat RR, Wong G, Curtin JP, et al: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55:164-168, 1994
70. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11:578-610, 1990
71. Love RR: Multisystem biological and symptomatic toxicity of tamoxifen in postmenopausal women, in Jordan VC (ed): Long-Term Tamoxifen Treatment for Breast Cancer. Madison, WI, University of Wisconsin Press, 1994, pp 57-83
72. Sutherland RL, Watts CK, Reunitz PC: Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. Biochem Biophys Res Comm 140:323-529, 1986
73. O'Brian CA, Liskamp RM, Solomon DH, et al: Inhibition of protein kinaseC by tamoxifen. Cancer Res 45:2462-2465, 1985
74. Lam HY: Tamoxifen is a calmodulin antagonist in the activation of camp phosphodiesterase. Biochem Biophys Res Comm 118:27-32, 1984
75. Knabbe C, Lippman ME, Wakefield LM, et al: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428, 1987
76. Glick AB, Danielpour D, Morgan D, et al: Induction and autocrine receptor binding of transforming growth factor-beta 2 during terminal differentiation of primary mouse keratinocytes. Mol Endocrinol 4:46-52, 1990
77. Pollak MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (1GF-1). Breast Cancer Res Treat 22:91-100, 1992
78. Cook LS, Weiss NS, Schwartz SM, et al: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J Natl Cancer Inst 87:1359-1364, 1995
79. Ribeiro G, Swindell R: The Christie Hospital Adjuvant Tamoxifen Trial. Monogr Natl Cancer Inst 11:121-125, 1992